Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | IGF2R | P11717 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12394539 | 0.87 | GJB2 (0.31) | GJB2 | |
| SCHEMBL10748231 | 0.86 | MAPK1 (0.42) | CA1CA2CA9MAPK1LGALS8 | |
| SCHEMBL25805555 | 0.81 | CA2 (0.42) | CA1CA2CA9MAPK1LGALS8 | |
| SCHEMBL15196544 | 0.81 | CA2 (0.42) | CA1CA2CA9MAPK1LGALS8 | |
| SCHEMBL12253287 | 0.80 | L3MBTL1 (0.35) | CA1CA2CA9MAPK1LGALS8 | |
| SCHEMBL19337537 | 0.78 | MAPK1 (0.38) | CA1CA2CA9MAPK1LGALS8 | |
| SCHEMBL13998032 | 0.77 | LGALS8 (0.43) | CA1CA2CA9MAPK1LGALS8 | |
| SCHEMBL31653946 | 0.76 | MAPK1 (0.43) | CA1CA2CA9MAPK1LGALS8 | |
| SCHEMBL14666291 | 0.75 | LGALS3 (0.49) | LGALS8LGALS3LGALS4IGF2R | |
| SCHEMBL13539943 | 0.71 | LGALS8 (0.44) | LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8043385-B2 | Composition oxidation colouring of keratinic fibres, containing a cationic cellulose ether, a metasilicate and oxidation dyes, method for oxidation colouring and uses thereof | L'OREAL S.A. (FR) | 2011-10-25 | — | — | US | disclosed |
| US-8002847-B2 | Composition for oxidation dyeing keratin fibres comprising a cationic cellulose ether, a weakly oxyethylenated sorbitan fatty acid ester and oxidation dyes | L 'OREAL S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20100275388-A1 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | L'OREAL S.A. (FR) | 2010-11-04 | — | — | US | disclosed |
| US-20100263138-A1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'OREAL S.A. (FR) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100275388-A1 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | KRT18, KRTCAP2, FASN | CA1 1925/4885CA2 1354/4885CA9 891/4885 |
| US-20100263138-A1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | KRT18, TUBB3, VIM | CA1 1097/4885CA2 1055/4885CA9 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.